TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06686030: An Exploratory, Multi-cohort Phase II Study of Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

Sponsor: Akeso · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06686030 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06686030 Rescue Dossier →